No Result
View All Result
Sunday, January 17, 2021
Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish
  • |
  • Tech
  • Medicine
  • Society
  • Environment
  • Spazio
  • Transportation
  • Weather
  • concepts
  • H+
No Result
View All Result

Covid-19 Updates »

November 23, 2020
in Medicine

There is no 2 without 3. AstraZeneca Covid-19 vaccine: how is it different?

Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

Collaborate!

We are open to visions about the future. Submit an article, disclose the results of a search or scientific discoveries, shows points of view on a theme, tells about a change.

CONTACT US
covid-19 astrazeneca vaccine
Share10Pin2Tweet6SendShare2
tags: astrazenecaCoronavirusCovid-19vaccine

An AstraZeneca vaccine at Covid-19 was also announced today. Here is a focus on positive results, on weaknesses and strengths,

Gianluca Ricciodi Gianluca Riccio
6 minutes of reading

The last

Zaha Hadid's Tower C in Shenzen looks like something out of Star Trek

Forestry robots can plant thousands of trees a day

Biden settlement, US survey: 79% of the country is collapsing

Neom, the linear city in Saudi Arabia will be 170km long

Take a look at the future world map

Read also:

Mobi, smart trolley that acts as a shopping assistant

Mobi, smart trolley that acts as a shopping assistant

personalized shampoo

Gemmist, personalized shampoo is growing in a still immature market

end of the pandemic

How will Covid-19 become at the end of the pandemic?

ArchelisFX, exoskeleton chair for standing

ArchelisFX, exoskeleton chair for standing

mental disorders

Mental disorders at CES2021: iSyncWave, diagnosis and portable therapy

lingkai, swab robot

Covid, China is using the Lingcai robot to make swabs

Milrem presents a fearsome robotic tank

Milrem presents a fearsome robotic tank

Bot Handy, Samsung presents the butler robot at CES2021

Bot Handy, Samsung presents the butler robot at CES2021

measure blood sugar without needles

CES2021, here is the smartwatch that can measure blood sugar without needles

vaccination center

Disneyland will transform into a giant vaccination center

MRNA vaccines: Covid today, Cancer tomorrow

MRNA vaccines: Covid today, Cancer tomorrow

Woodnest, the hanging houses with breathtaking views of the Norwegian fjord

Woodnest, the hanging houses with breathtaking views of the Norwegian fjord

Read also:

Zaha Hadid's Tower C in Shenzen looks like something out of Star Trek

Zaha Hadid's Tower C in Shenzen looks like something out of Star Trek

AstraZeneca announced today in a press release that its COVID-19 vaccine has shown positive results in the interim analysis of clinical trial data.

The announcement marks the third Covid-19 vaccine to show strong efficacy in late-stage studies against SARS-CoV-2. AstraZeneca's vaccine efficacy numbers are not as high as those of previous vaccines (mRNA vaccines from Pfizer / BioNTech e Modern). Nonetheless, AstraZeneca also offers some advantages over those vaccines.

And overall, the news adds optimism that vaccines could end the global crisis in the next year.

Maybe you are also interested

Nanomaterial biosensor detects Covid antibodies in 10-12 seconds

Good news: Covid immunity lasts perhaps for years or decades

A UV-LED kills Covid. The team: "Let's use it in ventilation systems"

Birth rate Italy, Covid knocks it down to the lowest levels ever

The Covid-19 AstraZeneca vaccine: the data

AstraZeneca collaborated with researchers from the University of Oxford to develop the viral vector based vaccine named AZD1222 (also called ChAdOx1 nCoV-19) . The vaccine involves encoding the genetic material for the infamous SARS-CoV-2 spike protein, which is carried around the body by a relatively benign virus. In this case, the virus is a weakened type of adenovirus, a pathogen that can cause common colds and other mild infections in humans and some animals.

The AZD1222 results announced today come from a pooled analysis of clinical trials conducted in the UK and Brazil, involving over 23.000 participants. AstraZeneca's independent monitoring committee found that AZD1222 was on average about 70% effective in preventing COVID-19, the disease caused by SARS-CoV-2. The interim analysis was triggered when 131 cases occurred in study participants who were given two doses of AZD1222 or a comparator vaccine, the meningococcal vaccine MenACWY. The efficacy rate is calculated based on how those 131 cases split into the MenACWY group compared to the AZD1222 group.

Two different dosages, two different results

The results were a little more complicated than that simple split. Participants who received AZD1222 got one of two dosing regimens, so the results were further split. 

In one regimen, participants were given a half dose of AZD1222 followed by a booster shot with a full dose. In studies, 2.741 participants got this regimen and it appeared about 90% effective in preventing COVID-19.

In the other regimen, participants receiving AZD1222 received two full doses of the vaccine. In other words, they got the same high dose level in their first shot as they did in their booster shot. In the studies, 8.895 participants got this regimen and it appeared about 62% effective in preventing COVID-19.

The pooled efficacy data yields an average efficacy of approximately 70%. This is impressive: the initial goal was around 50%. It is not as high as the staggering efficacy results of the mRNA vaccine reported in the previous weeks. The 95% of efficacy for the Pfizer / BioNTech vaccine and the 94,5% of effectiveness for Moderna.

Unexpected result, doubts and positive things

Let's start by saying what is not yet clear. First, it is unclear whether the 90% efficacy result will hold up as AstraZeneca collects more data and conducts further analysis. We do not yet know how the 131 cases were divided in the subgroup analyzes. The final efficacy number is very likely to change as more data is collected. 

On a positive note, the need for less vaccine in the first dose. If it turns out to be a winning solution, more people can be vaccinated with the same amount of vaccine production capacity.

Another positive note, albeit very preliminary. The Oxford researchers reported that the Covid-19 vaccine AstraZeneca AZD1222 appears to reduce asymptomatic SARS-CoV-2 infections. This finding is particularly surprising as mRNA vaccine studies only looked at symptomatic COVID-19 cases. However, the discovery is extremely preliminary as the researchers have not presented any data on it.

Covid-19 vaccine AstraZeneca: let's talk about safety

As with mRNA vaccines, AstraZeneca said no vaccine-related serious adverse events have been confirmed. In the results of previous studies, mild side effects from AZD1222 were common. These include pain, feeling of fever, chills, muscle aches, headache. Some participants were given paracetamol (acetaminophen / Tylenol) beforehand to reduce these effects.

If you remember, AstraZeneca has  interrupted his rehearsals at least twice , one in July and another in September, for standard safety reviews. The evidence they stopped in July when a UK participant showed neurological symptoms: later diagnosed with multiple sclerosis. In September, another participant developed symptoms consistent with transverse myelitis, a condition involving inflammation of the spinal cord that may, in rare cases, be linked to vaccination. Both cases were eventually dubbed unrelated to the vaccine itself and trials were resumed.

The huge advantage would be on distribution

A significant advantage of the AstraZeneca Covid-19 vaccine is that it would be relatively easy to increase production and does not require specialized storage conditions. Adenovirus vectors are more established in the vaccine arena, compared to mRNA-based vaccines, which are brand new. The capacity to produce large quantities of adenoviruses already exists.

AstraZeneca said in its press release that it is “making rapid progress in manufacturing with a capacity up to 3 billion vaccine doses in 2021 (against 1,3 billion for Pfizer and BioNTech, so to speak, and up to 1 billion for Moderna). The vaccine can be stored, transported and handled under normal refrigerated conditions (2-8 degrees Celsius / 36-46 degrees Fahrenheit) for at least six months and administered within existing health facilities. "

As is known, mRNA vaccines require different storage conditions. Specifically, the vaccine from Pfizer and BioNTech requires storage at an annoying temperature of -70 ° C. Moderna announced in a recent press release  that your vaccine remains stable for six months at -20 ° C (-4 ° F), up to 30 days at normal refrigerator temperature (2-8 ° C or 36-46 ° F), and up to 12 hours at room temperature. 

All three vaccines are now directed to regulators around the world for authorization. Pfizer unveiled the your request for emergency use authorization by the US Food and Drug Administration.

In summary

All three vaccines are yet to have their full datasets published, so much uncertainty about the data and analyzes remains. Efficacy numbers will likely change as studies continue, safety monitoring will lengthen, and peer reviewers will review the analyzes. Rare side effects are also more likely to occur over time.

While preliminary vaccine studies have suggested that they all stimulate a variety of immune responses in participants, how long any protection from any of these vaccines can last is completely unknown. It is still unclear what levels of immune responses equate to complete protection from a serious infection or disease. And in a one-year pandemic with a completely new pathogen for us, it is impossible to say for sure how long those protective immune responses will remain protective.

Finally, there is so far no data on how much vaccines protect against asymptomatic infections. Disease prevention, and especially life-threatening diseases, is the top priority in these studies. 

However, preventing asymptomatic or mild infections will be key to ending SARS-CoV-2 transmission.

Comment this post on all the social networks where Futuroprossimo.it is present ( Facebook, Instagram, Twitter, Telegram, Linkedin, Vkontakte, Flipboard )

The future of:

Artificial intelligence

Engineers use AI to convert ancient maps into satellite images

transhumanism

A special hyperbaric therapy can stop and reverse aging

Super Gadgets

CLIP, portable electric motor that turns every bike into an ebike

Design

Therapeutic tools like Balisa help patients see healing

Most read of the week

  • CLIP, portable electric motor that turns every bike into an ebike

    CLIP, portable electric motor that turns every bike into an ebike

    264 shares
    Share 106 Tweet 66
  • Australia, found the way to cure Crohn's disease

    7269 shares
    Share 6122 Tweet 478
  • Pentagon UFO task force ready to reveal its findings

    343 shares
    Share 137 Tweet 86

The last

DARPA at work on night vision goggles as large as normal glasses

Team develops new gene therapy to extend lifespan

Teleportation: is it really impossible? Where are we at?

AR Cloud, the new generation of "virtual life" superimposed on the real one

Wind turbines of today could become the bridges of tomorrow

Next article
shell 2030 city car futura

Shell 2030 can be your future electric city car

Futuroprossimo.it is an Italian resource of futurology opened since 2006: every day news about the near future. Scientific discoveries, medical research, prototypes, concepts and predictions about the future for free.

Tag

Environment Architecture Communication concepts Advice Energy Events Gadgets The future of yesterday The newspaper of tomorrow Medicine Military Weather Robotica Society Spazio Technology transhumanism Transportation Video

Categories

The author

Gianluca Riccio, copywriter and journalist - Born in 1975, he is the creative director of an advertising agency, he is affiliated with the Italian Institute for the Future, World Future Society and H +, Network of Italian Transhumanists.

Collaborate! Are you interested in writing a post on Futuroprossimo? Click here for contacts.

Home / Author / IDEA / archive / Promo on FP

© 2020 Futuroprossimo - Tailored by Be Here

© 2020 Futuroprossimo - Tailored by Be Here

  • Home
  • Contact us
  • archive
  • Technology
  • Medicine
  • Transportation
  • Weather
  • Society
  • Environment
  • transhumanism

© 2019 Futuroprossimo - Tailored by To be here

This site uses cookies. By continuing to read it, you consent to their use.